NYSE:ABBVAbbVie Stock Price, Forecast & News

AbbVie's stock was trading at $84.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ABBV stock has increased by 15.4% and is now trading at $97.90. View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AbbVie.

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, July 31st 2020. View our earnings forecast for AbbVie.

AbbVie will be holding an earnings conference call on Friday, July 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

AbbVie Inc (NYSE:ABBV) issued its quarterly earnings results on Friday, May, 1st. The company reported $2.42 EPS for the quarter, topping analysts' consensus estimates of $2.25 by $0.17. The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.31 billion. AbbVie had a net margin of 24.77% and a negative return on equity of 169.80%. The business's revenue for the quarter was up 10.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.14 EPS. View AbbVie's earnings history.

AbbVie declared a quarterly dividend on Wednesday, June 17th. Shareholders of record on Wednesday, July 15th will be paid a dividend of $1.18 per share on Friday, August 14th. This represents a $4.72 annualized dividend and a yield of 4.82%. The ex-dividend date of this dividend is Tuesday, July 14th. View AbbVie's dividend history.

AbbVie declared that its Board of Directors has approved a stock repurchase program on Thursday, December 13th 2018, which permits the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to reacquire up to 3.8% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board of directors believes its shares are undervalued.

AbbVie updated its FY 2020 After-Hours earnings guidance on Friday, May, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $50-50 billion.

17 equities research analysts have issued 12 month target prices for AbbVie's shares. Their forecasts range from $90.00 to $125.00. On average, they anticipate AbbVie's share price to reach $106.80 in the next twelve months. This suggests a possible upside of 9.1% from the stock's current price. View analysts' price targets for AbbVie.

Media headlines about ABBV stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AbbVie earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about AbbVie.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Bristol-Myers Squibb (BMY) and Valeant Pharmaceuticals Intl (VRX).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by many different institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.15%), DNB Asset Management AS (0.07%), Manning & Napier Group LLC (0.03%), State of Alaska Department of Revenue (0.02%), Raub Brock Capital Management LP (0.02%) and Factory Mutual Insurance Co. (0.02%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase. View institutional ownership trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, 6 Meridian, Factory Mutual Insurance Co., Municipal Employees Retirement System of Michigan, IFM Investors Pty Ltd, HNP Capital LLC, Raub Brock Capital Management LP, and Park National Corp OH. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Jeffrey Ryan Stewart, and Timothy J Richmond. View insider buying and selling activity for AbbVie.

ABBV stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Envestnet Asset Management Inc., State of Alaska Department of Revenue, Contravisory Investment Management Inc., Wesbanco Bank Inc., Veracity Capital LLC, Mountain Capital Investment Advisors Inc, and Canandaigua National Corp. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase. View insider buying and selling activity for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $97.90.

AbbVie has a market capitalization of $144.57 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

The official website for AbbVie is www.abbvie.com.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.